About Takeda Pharmaceuticals
Takeda Pharmaceuticals is a company based in Tokyo (Japan) founded in 1781. It operates as a Direct-to-Consumer (D2C) and Professional Services. The company has 47,450 employees as of March 31, 2024. Takeda Pharmaceuticals has completed 19 acquisitions, including Adaptate Biotherapeutics, Ariad Pharmaceuticals and IDM Pharma. Takeda Pharmaceuticals offers products and services including Oveporexton (TAK-861), Plasma-Derived Therapies, and Oncology Treatments.
- Headquarter Tokyo, Japan
- Employees 47450 as on 31 Mar, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Takeda Pharmaceutical Co. Ltd.
-
Annual Revenue
$30.65 B (USD)7.45as on Mar 31, 2025
-
Net Profit
$722.27 M (USD)-25.08as on Mar 31, 2025
-
EBITDA
$9.3 B (USD)10.28as on Mar 31, 2025
-
Latest Funding Round
$30.9 B (USD), Debt – Conventional
Nov 05, 2018
- Investors
-
Employee Count
47450
as on Mar 31, 2024
-
Investments & Acquisitions
Adaptate Biotherapeutics
& 18 more
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Takeda Pharmaceuticals
Takeda Pharmaceuticals is a publicly listed company on the TSE with ticker symbol 4502 in Japan, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Takeda Pharmaceuticals
Takeda Pharmaceuticals offers a comprehensive portfolio of products and services, including Oveporexton (TAK-861), Plasma-Derived Therapies, and Oncology Treatments.
Developed for treating narcolepsy type 1 in patients.
Innovated for chronic rare diseases using plasma technology.
Created to address cancer with innovative therapeutic solutions.
People of Takeda Pharmaceuticals
Unlock access to complete
Unlock access to complete
Software Development Team
330 people
Leadership Team
187 people
Data Analysis and Operations Team
65 people
Operations Team
60 people
Head Team
47 people
Legal and Compliance
43 people
Human Resources and Administration
42 people
Product Management Team
40 people
Unlock access to complete
Funding Insights of Takeda Pharmaceuticals
Investors in Takeda Pharmaceuticals
Takeda Pharmaceuticals has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Military Health.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Administers health care and support for military personnel and operations.
|
Locked | Locked | Locked |
Investor details for Takeda Pharmaceuticals
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Takeda Pharmaceuticals
Takeda Pharmaceuticals has strategically engaged in corporate development activities, having acquired 19 companies. Notable acquisitions include Adaptate Biotherapeutics, Ariad Pharmaceuticals and IDM Pharma.
Investment portfolio details for Takeda Pharmaceuticals
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
T-cell-based immunotherapies for cancer treatment are developed.
|
Locked | Locked | 2019 | Locked | |
|
Immunotherapeutics for cancer are developed using gamma delta T cells.
|
Locked | Locked | 2016 | Locked | |
|
Novel enzyme therapeutics for celiac disease are engineered.
|
Locked | Locked | 2015 | Locked |
Complete acquisition details for Takeda Pharmaceuticals
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Takeda Pharmaceuticals
Detailed financials for Takeda Pharmaceuticals
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Takeda Pharmaceuticals Comparisons
Peer comparison for Takeda Pharmaceuticals
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Takeda Pharmaceuticals
Detailed competitors of Takeda Pharmaceuticals
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Takeda Pharmaceuticals
Complete news archive for Takeda Pharmaceuticals
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Takeda Pharmaceuticals
Takeda Pharmaceuticals was founded in 1781 and raised its 1st funding round 230 years after it was founded.
Takeda Pharmaceuticals is headquartered in Tokyo, Japan. It is registered at Tokyo, Tokyo, Japan.
As of Mar 31, 2024, the latest employee count at Takeda Pharmaceuticals is 47,450.
Annual revenue of Takeda Pharmaceuticals is $30.65B as on Mar 31, 2025.
Takeda Pharmaceuticals is involved in the research, development, and manufacturing of innovative medicines. Focus areas include gastrointestinal and inflammatory diseases, rare diseases, plasma-derived therapies, oncology, neuroscience, and vaccines. Solutions are provided to address unmet medical needs worldwide, with operations spanning multiple countries. Sustainability and corporate responsibility are integrated into the business strategy to enhance climate-resilient health systems.
Takeda Pharmaceuticals offers Oveporexton (TAK-861), Plasma-Derived Therapies, and Oncology Treatments.
Yes, Takeda Pharmaceuticals is publicly traded on TSE under the ticker symbol 4502.
Takeda Pharmaceuticals has made 19 acquisitions, including Adaptate Biotherapeutics, Ariad Pharmaceuticals, and IDM Pharma.
Takeda Pharmaceuticals has 1 investor. Key investors include Military Health.
The ticker symbol of Takeda Pharmaceuticals is 4502 on TSE.